Neurology

Journal Club ft. NEJM publications

Questions discussed in this category

How will your approach to screening and diagnosis of early dementia change given newly available therapies for early Alzheimer's disease?

5 Answers available

How clinically meaningful are the differences in the primary outcome between treatment and placebo groups in the CENTAUR trial?

Will these results change your practice?

5 Answers available

Would you avoid combining JAK inhibitors with IVIG given the risk of thromboembolism?

4 Answers available

How do you explain the clinical benefit of lecanemab or donanemab to patients?

Do you feel the study outcomes are clinically meaningful?

3 Answers available

Is there a point at which further reduction in amyloid burden is no longer clinically meaningful or should the goal always be as much reduction as possible?

4 Answers available

How will you counsel patients regarding ARIA?

Do you see utility in trending serum neurofilament light chain levels or any alternative screening methods beyond MRI to help identify amyloid-related...

2 Answers available

How do you recommend tapering IVIG in patients whose inflammatory myositis has achieved remission?

4 Answers available

What makes a patient a good candidate for treatments targeting amyloid such as lecanemab or donanemab?

Are there patients in whom you would specifically avoid this class of treatments?

2 Answers available

Which myositis patients are good candidates for IVIG?

3 Answers available

How long can you treat dermatomyositis with IVIG?

3 Answers available

Would the concerns about respiratory side effects from sodium phenylbutyrate and taurusodiol change your management of patients with predominantly bulbar ALS?

3 Answers available

How do you counsel patients on the side effects of sodium phenylbutyrate and taurursodiol?

3 Answers available

Do you typically assess plasma levels of the phosphorylated axonal neurofilament H subunit (pNF-H) in patients with ALS?

3 Answers available

Based on its mechanism of action, do you think sodium phenylbutyrate and taurursodiol could have benefit in other neurodegenerative disorders?

3 Answers available

Does the overall conclusion of the CHANCE-2 trial make ticagrelor + ASA a worthwhile transition given the data showing cumulative hazard of stroke diverged during the first week and was subsequently similar, which suggests the benefit of ticagrelor over clopidogrel is seen predominantly soon after stroke?

4 Answers available

Is there a risk of CYP2C19 gene testing only being adopted by wealthier health systems, thereby creating a disparity gap in treatment?

What is the cost and accessibility of CYP2C19 gene testing? Does the limited availability of rapid genotyping techniques limit the clinical applicabil...

3 Answers available

Would you generalize the data from the CHANCE-2 trial to a broader clinic population given that the study was specific to Han Chinese patients?

How do you plan to incorporate the results of the CHANCE-2 trial (Wang et al., PMID 34708996) in your own practice?

3 Answers available

Do you recommend genetic testing after a patient on clopidogrel has a stroke based on the results of the CHANCE-2 trial?

3 Answers available